Details

Autor(en) / Beteiligte

• Murphy, R.
• Green, S.
• Ritter, G.
• Cohen, L.
• Ryan, D.
• Woods, W.
• Rubira, M.
• Cebon, J.
• Davis, I. D.
• Sjolander, A.
• Kypridis, A.
• Kalnins, H.
• McNamara, M.
• Moloney, M. B.
• Ackland, J.
• Cartwright, G.
• Rood, J.
• Dumsday, G.
• Healey, K.
• Maher, D.
• Maraskovsky, E.
• Chen, Y.-T.
• Hoffman, E. W.
• Old, L. J.
• Scott, A. M.

Titel

Recombinant NY-ESO-1 Cancer Antigen: Production and Purification under cGMP Conditions

Ist Teil von

• Preparative biochemistry & biotechnology, 2005-01, Vol.35 (2), p.119-134

Ort / Verlag

England: Taylor & Francis Group

Erscheinungsjahr

2005

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His 6 -tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.